Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Electrocore Llc (ECOR)
NASDAQ:ECOR
Holding ECOR?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.3Last Year’s EPS
-$0.61Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: 13.96%
|Next Earnings Date:Mar 06, 2025
Earnings Call Sentiment|Positive
The overall sentiment of the call was positive, driven by record revenue growth, strong performance in the VA channel, and significant improvements in financial metrics. However, challenges remain in the TAC-STIM product line and the US prescription channel, alongside high operating expenses.Company Guidance
During the electroCore Q3 2024 earnings call, key financial and operational metrics highlighted the company's robust growth and strategic direction. Revenue reached $6.6 million, marking a 45% increase from the prior year, with a consistent gross margin of 84%. The company's net loss narrowed by 38% compared to Q3 2023, reflecting improved financial health. electroCore's prescription gammaCore therapy, especially in the VA channel, showed significant growth, with sales increasing by 75% to $4.8 million. Truvaga, their direct-to-consumer wellness line, recorded net sales of $657,000, a 147% increase year-over-year, with a return on advertising spend of 2.53. The pipeline for TAC-STIM, aimed at military use, also showed promise with a $550,000 order post-quarter. The company maintains a positive cash flow outlook, supported by $13.2 million in cash reserves, as it explores further growth avenues, including new channels and product lines.Record Revenue Growth
Revenue for the third quarter of 2024 was $6.6 million, marking a 45% increase over the prior year. This quarter is the eighth consecutive record revenue quarter for electroCore.
VA Channel Expansion
Sales in the VA channel grew 75% to $4.8 million in the third quarter of 2024, with 166 VA facilities purchasing prescription gammaCore products, up from 141 the previous year.
Truvaga Sales Surge
Truvaga net sales increased by 147% to approximately $657,000 in Q3 2024, compared to $266,000 in Q3 2023. Truvaga was also featured in Men's Health 2025 Tech Awards.
Improved Financial Metrics
Gross profit increased by $1.6 million, and net loss was reduced by 38% compared to the same period in 2023. Cash used in operations decreased by 51%.
Air Force Contract
On October 1, 2024, electroCore filled a $550,000 Air Force purchase order for TAC-STIM, indicating strong demand for this product line.
---
ECOR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ECOR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $13.40 | $13.60 | +1.49% |
| Aug 07, 2024 | $6.10 | $6.02 | -1.31% |
| May 08, 2024 | $7.24 | $6.85 | -5.39% |
| Mar 13, 2024 | $6.45 | $6.09 | -5.58% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Electrocore Llc (ECOR) report earnings?
Electrocore Llc (ECOR) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Electrocore Llc (ECOR) earnings time?
Electrocore Llc (ECOR) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ECOR EPS forecast?
ECOR EPS forecast for the fiscal quarter 2024 (Q4) is -$0.3.
---